Featured Publications
Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial
Shah N, Ghazi L, Yamamoto Y, Kumar S, Martin M, Simonov M, Riello Iii R, Faridi K, Ahmad T, Wilson F, Desai N. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial. Circulation Cardiovascular Quality And Outcomes 2024, 17: e010335. PMID: 38634282, DOI: 10.1161/circoutcomes.123.010335.Peer-Reviewed Original ResearchElectronic health recordsElectronic health record alertsHigh-risk atherosclerotic cardiovascular diseaseLipid lowering therapyAtherosclerotic cardiovascular diseasePragmatic trialCardiovascular diseaseProportion of patientsYale New Haven HealthLDL-CSecondary outcomesPrimary outcomeInternal medicine cliniciansEHR alertUsual careHealth recordsProvider levelCluster-randomizedLDL-C managementLDL-C levelsAdverse cardiovascular eventsRandomized clinical trialsTreatment of hyperlipidemiaCliniciansCardiovascular events
2022
Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyAtherosclerotic cardiovascular diseaseTreatment of hyperlipidemiaProportion of patientsElectronic health recordsPragmatic trialHigh riskCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHigh-risk atherosclerotic cardiovascular diseaseSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol reductionImportant public health implicationsEnrollment of patientsPublic health implicationsUsual careSecondary outcomesPrimary outcomeGuideline recommendationsCholesterol reductionPatientsLDLHyperlipidemiaScalable interventionsOutpatients